{
    "nctId": "NCT01377324",
    "briefTitle": "Molecular Imaging of Fulvestrant Effects on Availability of ER Binding Sites",
    "officialTitle": "In Vivo Imaging of the Effect of Fulvestrant on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Tumor Lesions Using FES-PET",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 16,
    "primaryOutcomeMeasure": "Visualize and quantify changes in FES uptake in tumor lesions during fulvestrant 500mg therapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 1. Patients with a history of histological proven ER-positive primary breast cancer and, whenever available, histological proven ER-positive recurrence. 2. Post-menopausal status (age \u2265 45 years with amenorrhea for \\> 12 months or prior bilateral ovariectomy 3. Documentation of a negative pregnancy test must be available for women less than 2 years after menopause 4. Progressive disease after 2 lines of hormonal therapy 5. No previous fulvestrant treatment 6. ER-antagonists should be discontinued for 5 weeks prior to FES-PET to prevent false negative FES-PET results. The use of aromatase inhibitors is allowed 7. ECOG performance status 0, 1 or 2 8. Life expectancy \\> 3 months 9. Creatinine clearance \u2265 30 ml/min 10. Age \u2265 18 years 11. Signed written informed consent 12. Able to comply with the protocol\n\nExclusion Criteria:\n\n* 1. Evidence of central nervous system metastases 2. Presence of life-threatening visceral metastases 3. \\> 3 lines of endocrine therapy for metastatic disease 4. \\> 2 lines of chemotherapy in metastatic disease",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}